Gamma1-Selective Benzodiazepine Modulators for GABA-A Side-Effect Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacological treatments for ASD and its associated comorbidities are limited in addressing the core symptoms and associated comorbidities of ASD, such as anxiety and irritability, with existing treatments like antipsychotics providing inadequate relief.
Innovation Solution
Development of benzodiazepine derivatives that act as selective GABA A γ1 receptor positive allosteric modulators (PAMs) to enhance GABAergic signaling in key brain regions, thereby rebalancing inhibitory neurotransmission and addressing the symptoms of ASD and other neurological disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective benzodiazepines are used to enhance GABAergic signaling, then therapeutic benefits for anxiety and neurological disorders are achieved, but side effects such as sedation and cognitive impairment occur due to non-selective receptor activation
Solution Approach 1:
The patent applies local quality by designing benzodiazepine derivatives with specific molecular structures that confer selectivity for GABA-A receptor subtypes containing the γ1 subunit. This structural modification enables the compound to preferentially bind to and modulate specific receptor locations in the brain (such as those in the limbic system and cortical areas) while avoiding non-selective activation of other GABA-A receptors, thereby achieving therapeutic effects with reduced side effects.
Solution Approach 2:
The patent segments the GABA-A receptor population by creating compounds that selectively target receptors containing the γ1 subunit versus other subtypes (such as those containing γ2, α1, or α2 subunits). This segmentation allows differential modulation of receptor populations, enabling selective enhancement of GABAergic inhibition in specific neural circuits involved in anxiety and neurological disorders without causing the broad sedative effects associated with non-selective benzodiazepines.
2Adaptability or versatility
If current pharmacological treatments (antipsychotics) are used for ASD symptoms, then some associated comorbidities are addressed, but core symptoms and many comorbidities remain inadequately treated
Solution Approach 1:
The patent applies parameter changes by modifying the molecular parameters of benzodiazepine derivatives to achieve selective binding affinity for GABA-A receptors containing the γ1 subunit. This parameter optimization (selectivity profile) enables the compound to effectively treat core symptoms of ASD and associated comorbidities by targeting specific neural circuits, thereby expanding treatment coverage and improving therapeutic efficacy compared to non-selective antipsychotic medications.
3Object-affected harmful factors
If GABA A γ1 selective PAMs are developed, then selective enhancement of GABAergic currents is achieved, but compound development and selectivity validation become more complex
Solution Approach 1:
The patent addresses the complexity of compound development by establishing specific structural features and molecular parameters that confer γ1 subunit selectivity. By defining these local quality requirements (specific binding site interactions, molecular configuration), the patent provides a framework for developing selective compounds that reduce side effects while managing the complexity through structured molecular design criteria.
Data Source
AI summary
The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein the variables are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds for the treatment or prevention of acute neurological disorders, chronic neurological disorders and/or cognitive disorders.